“Velcro-type” crackles predict specific radiologic features of fibrotic interstitial lung disease
- Submitting institution
-
University of Southampton
- Unit of assessment
- 12 - Engineering
- Output identifier
- 37763957
- Type
- D - Journal article
- DOI
-
10.1186/s12890-018-0670-0
- Title of journal
- BMC Pulmonary Medicine
- Article number
- 103
- First page
- -
- Volume
- 18
- Issue
- 1
- ISSN
- 1471-2466
- Open access status
- Compliant
- Month of publication
- June
- Year of publication
- 2018
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
13
- Research group(s)
-
-
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- This paper proposes an outcome measure that could be used in drug trials for drugs to tackle ideopathic pulmonary fibrosis (IPF) - a disease which is increasingly prevalent, and currently incurable but for which disease modifying drugs which slow its progress in some cases have recently become available. The work was funded by Intermune Inc (£50,000), subsequently taken over by Roche Holding AG, who developed the first IPF disease modifying drug, pirfenidone.
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -